Corticosteroid Exposure in the Treatment of Severe COPD Exacerbations

Abstract

Background:

Recent literature and guidelines support treatment of severe acute exacerbation of COPD (AECOPD) with prednisone 40 mg (or equivalent) for 5 days.

Objective:

The purpose of this study was to determine whether systemic corticosteroids were being prescribed at the appropriate dose and duration in the treatment of severe AECOPD at a large academic medical institution.

Methods:

This was a single-center, retrospective, observational study conducted to evaluate corticosteroid prescribing patterns for adults admitted for severe AECOPD from March to May 2019 at a large academic medical institution. Appropriate therapy was defined as: prednisone 40 mg (or equivalent) for 5 days. The primary outcome was to determine the frequency of appropriate dose and duration. The secondary outcomes were to identify the frequency of appropriate dose or duration, compare the prevalence of adverse effects, such as new/worsening hyperglycemia or hypertension, and compare 30- and 90-day readmission rates.

Results:

Of the 190 patients included, 16 (8.4%) had an appropriate duration and 8 (4.2%) an appropriate dose. Only 4 patients (2.1%) had both appropriate corticosteroid dose and duration. New/worsening hyperglycemia occurred in 96 (50.5%), and hypertension developed in 13 (6.8%). Thirty-day readmission occurred in 46 (24.2%) and 90-day readmission in 78 (41.1%). These were more likely in those without appropriate dose and duration.

Conclusion:

Systemic corticosteroids for the treatment of severe AECOPD are not prescribed in accordance with evidence-based recommendations at this institution. This might result in a greater incidence of adverse effects and readmissions.

Keywords

pulmonology chronic obstructive pulmonary disease systemic corticosteroids severe exacerbations appropriate dosing

Get full access to this article

View all access options for this article.

References

MacNee

. ABC of chronic obstructive pulmonary disease: pathology, pathogenesis, and pathophysiology. BMJ. 2006;332(7551):1202–1204.

Global initiative for chronic obstructive lung disease. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2019 Report. GOLD; 2019.

Groenewegen

Schols

Wouters

. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124(2):459–467.

Narum

Westergren

Klemp

. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2019;4(5):1–9.

Leuppi

Scheutz

Bingisser

, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–2231.

Walters

JAE

Tan

White

Wood-Baker

. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Syst Rev. 2018;2018(3):CD006897.

Sivapalan

Ingebrigtsen

Rasmussen

, et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67,000 patients with COPD followed for 12 months. BMJ Open Respir Res. 2019;6(1):e000407.

Rogers

Lin

Nallamothu

Kim

. Longitudinal study of short-term corticosteroid use by working-age adults with diabetes mellitus: risks and mitigating factors. J Diabetes. 2018;10(7):546–555.